Ann: Expanded Heart Protection Discovery for Zantrene, page-96

I think that for the benefit of patients any upfront cash is best used to accelerate large-scale trials and other research programs (there may also be conditions in a partnership on how upfront cash is used). I think Zantrene has high probability of being designated a breakthrough therapy by the FDA for use in combination with Doxorubicin and in combination with carfilzomib. There is significant potential here for Zantrene as a cardio-protective and synergistic anti-cancer agent to make a massive difference to patient outcomes. The faster this occurs, the better for patients and their families. I would prefer to see cash from partnership prioritised on this objective.

Royalty and future dividends from royalties could be part of a longer term picture.

One consideration is that distribution of dividends could force a situation triggering the need for shareholders to pay tax (depending on their own personal tax situation). This needs to be contrasted with shareholders being able to control when they convert unrealised profits into taxable gains.